- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
See AlsoAvera: Total Protein and A/G RatioStillwater Medical | Total Protein and A/G RatioPOS1513-HPR THE USE OF SUPRAMAXIMAL VERIFICATION TESTING FOR DETERMINING A ‘TRUE’ MAXIMAL EFFORT DURING CARDIOPULMONARY EXERCISE TESTING IN PEOPLE WITH RHEUMATOID ARTHRITIS AND PHYSICALLY INACTIVE NON-RA CONTROLSUrine Protein-Creatinine Ratio Test: What It Measures, Levels - Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- AB1049 BAFF-MRNA EXPRESSION IN PERIPHERAL BLOOD VERSUS RENAL TISSUE IN ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Publication Only
Systemic lupus erythematosus
AB1049 BAFF-MRNA EXPRESSION IN PERIPHERAL BLOOD VERSUS RENAL TISSUE IN ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
- A. Beltagy1,
- R. S. Z. Taleb2,
- M. Allam3,
- R. Mahmoud1,
- A. El-Girby4,
- A. Abdelati5
- 1Faculty of Medicine, Alexandria University, Department of Internal Medicine, Rheumatology Unit, Alexandria, Egypt
- 2Faculty of Medicine, Alexandria University, Department of Clinical and Chemical Pathology, Alexandria, Egypt
- 3Faculty of Medicine, Alexandria University, Department of Pathology, Alexandria, Egypt
- 4Faculty of Medicine, Alexandria University, Egypt., Department of Internal Medicine, Rheumatology Unit, Alexandria, Egypt
- 5Faculty of Medicine, Alexandria University, Egypt., Department of Internal Medicine, Rheumatology Unit, Alexandria, Egypt
Abstract
Background: Systemic Lupus Erythematosus (SLE) is an auto-immune disease that affects multiple systems in the body. Up to half of SLE patients develop Lupus Nephritis, which is classified into six classes, with classes III and IV being the most proliferative. Lupus Nephritis (LN) severity and prognosis are influenced by clinical and laboratory biomarkers. B-cell activating factor (BAFF) plays a fundamental role in pathogenesis of SLE. Belimumab, an immunoglobulin G targeting BAFF, is FDA-approved for treating active, autoantibody-positive adult SLE. Recent studies show increased efficacy when adding belimumab to standard therapy for managing LN. Although there is great difficulty in finding reliable markers for stratifying patients and predicting prognosis, BAFF is still under investigation as a potential biomarker. [1]
Objectives: The objectives of the study were to assess the difference in baseline peripheral and renal tissue BAFF expression in active proliferative (pLN), and the correlation with different baseline and response assessment parameters.
Methods: Patients diagnosed with active pLN were recruited from Alexandria Main University Hospital lupus clinic and followed for 6 months after start of standard induction protocol with pulse corticosteroid therapy followed by either mycophenolate mofetil (MMF), or IV euro-lupus cyclophosphamide (followed by either MMF or azathioprine).
At baseline, patients were assessed clinically and by testing for routine lab parameters as well as urinary protein creatinine ratio (uPCR), serologic markers, and activity markers (SLEDAI-2K and rSLEDAI), obtaining renal biopsy for classification and activity versus chronicity evaluation, Measuring peripheral mononuclear cell (pMNC) BAFF expression and intrarenal BAFF expression using RT quantitative PCR was done at baseline only.
After 6 months of the start of treatment, the same parameters were reassessed. Renal response was defined as “the reduction of u-PCR by 50% or more and a normal or nearly-normal GFR (or, if previously abnormal, within 10% of the range of normal GFR. [2]
Results: The study included 15 patients with early active pLN: median age = 24 years (range 17-42), 13 females, 7 class III ± V, 8 class IV ± V, 9 responders (R) versus 6 non-responders (NR), median activity index = 9 (range: 4-13), median chronicity index 3 (range 0-8).
At baseline, median renal BAFF-mRNA expression was higher than peripheral pMNC expression, but it was statistically non-significant (p= 0.97)
pMNC BAFF-mRNA was only positively correlated with age at the onset of LN (r= 0.534, p= 0.04) and negatively correlated to serum albumin level (r= -0.725, p=0.012) while renal BAFF-mRNA was only strongly correlated with the increase in uric acid level (r= 0.782, p=0.013).
Both studied parameters did not correlate with baseline serological measures, SLEDAI, rSLEDAI or histopathological parameters.
Both baseline median intrarenal and pMNC BAFF-mRNA were higher in patients who showed an early 6-month reduction in proteinuria >50% (responders), however, the difference in intrarenal BAFF-mRNA was more pronounced (Figure 1).
Lower intrarenal BAFF-mRNA correlated better than pMNC expression with a reduction in uPCR and reduction in creatinine after 6 months (Figure 2)
- Download figure
- Open in new tab
- Download powerpoint
Figure 1.
Difference in pMNC and renal BAFF-mRNA between responders and non-responders.
- Download figure
- Open in new tab
- Download powerpoint
Figure 2.
Difference in correlation between pMNC and renal BAFF-mRNA with renal response parameters
Conclusion: The study result indicate that renal tissue BAFF expression is superior to peripheral expression in the representation of activity and prognosis of LN, however, these results were not statistically significant.
REFERENCES: [1] Tektonidou et al. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis & rheumatology. 2016.
[2] Rovin BH, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2020
Acknowledgements: NIL.
Disclosure of Interests: None declared.
- Cytokines and Chemokines
- Biomarkers
- Kidneys
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Cytokines and Chemokines
- Biomarkers
- Kidneys
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens